INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Mark Lowdell, Ph.D., will deliver the opening plenary lecture at the International Society of Cell and Gene Therapy (ISCT) in Paris on May 31st. The talk, titled 'The Future of Immune Effector Cell Therapies for Cancer, Tumor-Primed Memory NK Cells – from Heresy to Clinical Trials,' will focus on INKmune™, the company's proprietary Natural Killer (NK) cell platform.
Dr. Lowdell's team has discovered that INKmune™ primes NK cells to a unique cancer-killing population of memory-like NK cells, differing from cytokine-primed NK cells. This breakthrough could potentially avoid complications associated with cytokine therapy. The company recently received FDA acceptance of its Investigational New Drug Application (IND) for treating metastatic castrate-resistant prostate cancer, with a Phase I/II study set to begin enrolling patients in the US later this year.
Summary not available.
Summary not available.
INmune Bio, Inc. (NASDAQ: INMB) will host a conference call on May 3, 2023 at 4:30 PM ET to discuss first-quarter results ending March 31, 2023 and provide a corporate update. Participants can join by dialing 1-844-826-3035 for U.S. and 1-412-317-5195 for international calls. The conference ID is 10177985. A live audio webcast will also be available. A transcript will be provided 24 hours after the call, with a replay option available until May 10, 2023.
INmune Bio focuses on developing treatments leveraging the innate immune system for diseases such as cancer and Alzheimer's. Its key platforms involve ongoing clinical trials for novel therapies, including INB03™ and XPro™, highlighting its innovative approach in precision medicine.
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company, announced promising pre-clinical data indicating that its compound XPro™ can prevent Alzheimer’s Disease (AD) related amyloid pathology following Traumatic Brain Injury (TBI). The research, led by Kirsty J. Dixon from Virginia Commonwealth University, shows that soluble TNF contributes to amyloid development post-TBI. Treatment with XPro™ one hour after TBI effectively neutralizes soluble TNF and prevents amyloid formation, suggesting potential for early intervention in preventing AD, particularly in the elderly, who are most at risk from TBI. The findings were presented at the AD/PD™ 2023 conference on April 1, 2023. XPro™ is a next-generation TNF inhibitor showing potential in treating neurologic diseases by reducing neuroinflammation.
INmune Bio, Inc. (NASDAQ: INMB) has presented significant findings at the American Association of Cancer Research Annual Meeting 2023 regarding INB03, a dominant-negative TNF inhibitor. Targeting high-risk MUC4 expressing HER2+ and triple-negative breast cancer, INB03 reverses resistance mechanisms to immunotherapy. MUC4 presence correlates with poor survival and treatment resistance, intensifying metastatic potential. INB03 decreases MUC4 expression and enhances the effectiveness of trastuzumab-based therapies. Additionally, the Phase I trial of INB03 reported it as safe and well-tolerated, with no dose-limiting toxicity. The company plans to initiate a Phase II trial, signifying a critical step in developing more effective treatment combinations.
INmune Bio (NASDAQ: INMB) has submitted an Investigational New Drug (IND) application to the FDA for its INKmune™ therapy aimed at treating metastatic castration-resistant prostate cancer (mCRPC). This trial, involving approximately 30 patients across multiple medical centers, focuses on assessing safety and determining the optimal dosage. The therapy seeks to convert patients' NK cells into cancer-fighting memory-like NK cells. Additionally, initial data from ongoing trials shows promising tumor-killing memory-like NK cells in patients without adverse side effects. The company emphasizes the potential of INKmune™ as a viable alternative to traditional chemotherapy.
INmune Bio, Inc. (NASDAQ: INMB) announced its financial results for the year ended December 31, 2022. The company reported a net loss of approximately $27.3 million, down from $30.3 million in 2021. R&D expenses were $17.1 million, a decrease from $20.5 million year-over-year. The firm highlighted advancements in its DN-TNF platform, merging trial efforts for Mild Cognitive Impairment and Alzheimer's Disease. It also received about $6.4 million in R&D rebates to enhance patient enrollment. The FDA review regarding a clinical hold on XPro™ AD trial is ongoing, with a Phase 2 trial anticipated to begin upon resolution. Cash reserves as of December 31, 2022, stood at $52.2 million.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for March 2, 2023, at 4:30 PM ET. The call aims to discuss the results of its fourth quarter ending December 31, 2022, alongside a corporate update. Participants can join by dialing 1-877-407-0784 for domestic calls or 1-201-689-8560 internationally. A live webcast will also be available. Following the call, a transcript will be released approximately 24 hours later, and a replay can be accessed until March 9, 2023.
INmune Bio focuses on developing treatments that leverage the innate immune system against diseases, with ongoing clinical trials for its product platforms.
INmune Bio, Inc. (NASDAQ: INMB) announced it has received approximately $6.4 million in R&D refunds from Australia (~$3.7 million) and the UK (~$2.7 million). These funds will be reinvested into clinical programs, notably the ongoing Phase 2 Alzheimer’s Disease trial in Australia and Canada.
This non-dilutive funding will enhance recruitment and enrollment efforts, with plans to expand the trial internationally. CFO David Moss emphasized the importance of these rebates for continued collaboration with the FDA on the U.S. trial.